Eohilia (Budesonide) Patent Expiration, LOE Window & CMS Spending
Eohilia (Budesonide) by Takeda: FDA Orange Book LOE 2039-01-10, 8 AB generics, $4.1M 2024 CMS Part D & Medicaid spend, and $1,875 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Takeda |
| FDA Application & Pathway | N213976 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2039-01-10 |
| Orange Book Patents (*PED Extensions) | 12 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $4.1M |
| 2024 Medicare Part D Spend | $1.6M |
| 2024 Medicaid Spend | $2.6M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,875 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.